Combinatorial approach to develop novel pre-therapeutic agents targeting virulence factors essential to clinically relevant pathogens
开发针对临床相关病原体必需毒力因子的新型治疗前药物的组合方法
基本信息
- 批准号:10424305
- 负责人:
- 金额:$ 6.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-06 至 2022-01-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibiotic ResistanceAntibiotic TherapyAntibioticsAspartateBindingBinding ProteinsBiochemicalBiological AssayCalorimetryCause of DeathCell DeathChemicalsClostridium difficileColitisComputer AssistedConsumptionDevelopmentESKAPE pathogensEnzyme ActivationFoundationsFutureHealthLearningLegal patentMembraneMentorsMethodsMicrobeMolecular TargetMusNatural ProductsNosocomial InfectionsOutcomePathogenicityPeriodicityPhasePhospholipase A2ProcessProteinsPseudomonas aeruginosaResearchResistanceResolutionSerineStructureStructure-Activity RelationshipTechniquesTimeTitrationsType III Secretion System PathwayVirulenceVirulence FactorsX-Ray Crystallographyacute infectionalgorithm developmentantimicrobial drugbaseclinically relevantcofactorcombinatorialcostdrug discoveryglobal healthinhibitor/antagonistlead optimizationmacromoleculemicrobiotanovelpathogenpressurepreventskillssmall moleculetargeted treatmenttraitvirtual screening
项目摘要
Project Summary/Abstract
Antibiotic resistance is a serious global health threat. Current antibiotics target essential bacterial processes
and impose strong selective pressure for resistance. Upon antibiotic treatment, the healthy microbiota are
reduced in both number and diversity, leading to serious health consequences such as Clostridium difficile
colitis. Moreover, resistant traits can be transferred to other microbes, leading to the spread of antibiotic
resistance. Using virulence blockers to target specific pathogenicity mechanisms, while leaving the microbiota
intact, is a promising strategy to reduce resistance. This proposal will identify molecular target of a newly
discovered the type III secretion system (T3SS) inhibitor, and explore their modes of action for further
optimization and development. I will assess structure – activity relationship to optimize the T3SS inhibitors,
cyclic pepeptomers, and use affinity based method to identify their molecular targets in Pseudomonas
aeruginosa. Besides, target-based drug discovery offers the advantage of being low cost and less time
consuming. With the availability of high-resolution structure and development of algorithms to predict binding
affinity and poses of small molecules to its protein target, virtual screening can provide lead for optimization.
ExoU, an effector with phospholipase A2 activity, is the major effector in P. aeruginosa, one of six ESKAPE
pathogens which cause the majority of nosocomial infections in the U.S. and “escape” antimicrobial drugs.
ExoU has a serine/aspartate catalytic dyad and a separate cofactor-binding domain required for activation of
the enzyme. ExoU is highly toxic, associated with acute infection, antibiotic resistance and severe outcome in
patents. Delay ExoU expression can increase mice survival. Thus we set out to find ExoU inhibitors as a
strategy to treat acute infection and reduce resistance. We will identify ExoU inhibitors that 1) inhibit enzymatic
activity by targeting its catalytic residue serine, or 2) bind to the membrane localization domain which will
prevent ExoU’s activation by virtual screening. The inhibitors that show binding affinity to ExoU in isothermal
titration calorimetry assay, and prevent cell death caused by ExoU will be chosen for optimization. Structure of
inhibitor-bound proteins will be solved using X-ray crystallography. I believe that my team of mentors (Drs.
Stone and Ottemann), advisors (Dr. Rubin, expert in X-ray crystallography; Dr. Jacobson, expert in computer-
aided drug discovery) and collaborators (Dr. Lokey, an expert in macromolecule synthesis, Drs. Crews and
Linington, natural product chemists) will provide me support to successfully carry out this project. With the
biochemical techniques I will learn, the structures and new inhibitors I will obtain in the K99 phase, I will then
collaborate with Dr. Shaw (medicinal chemist) and Dr. Jacobson to optimize the candidate hits in my
independent phase. This project extends my skill set in biochemical methods and has the potential to provide
substantial momentum towards drug discovery, and development. These will serve as the foundation of a R01
proposal to be prepared upon the completion of the main stages of this research plan.
项目总结/文摘
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Developing Cyclic Peptomers as Broad-Spectrum Type III Secretion System Inhibitors in Gram-Negative Bacteria.
- DOI:10.1128/aac.01690-20
- 发表时间:2021-06-17
- 期刊:
- 影响因子:4.9
- 作者:Lam HN;Lau T;Lentz A;Sherry J;Cabrera-Cortez A;Hug K;Lalljie A;Engel J;Lokey RS;Auerbuch V
- 通讯作者:Auerbuch V
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hanh Ngoc Lam其他文献
Hanh Ngoc Lam的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hanh Ngoc Lam', 18)}}的其他基金
Combinatorial approach to develop novel pre-therapeutic agents targeting virulence factors essential to clinically relevant pathogens
开发针对临床相关病原体必需毒力因子的新型治疗前药物的组合方法
- 批准号:
10681469 - 财政年份:2019
- 资助金额:
$ 6.16万 - 项目类别:
Combinatorial approach to develop novel pre-therapeutic agents targeting virulence factors essential to clinically relevant pathogens
开发针对临床相关病原体必需毒力因子的新型治疗前药物的组合方法
- 批准号:
10659294 - 财政年份:2019
- 资助金额:
$ 6.16万 - 项目类别:
相似海外基金
Ecological and Evolutionary Drivers of Antibiotic Resistance in Patients
患者抗生素耐药性的生态和进化驱动因素
- 批准号:
EP/Y031067/1 - 财政年份:2024
- 资助金额:
$ 6.16万 - 项目类别:
Research Grant
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
- 批准号:
2307222 - 财政年份:2024
- 资助金额:
$ 6.16万 - 项目类别:
Standard Grant
Molecular Epidemiology of Antibiotic Resistance in Clostridioides difficile
艰难梭菌抗生素耐药性的分子流行病学
- 批准号:
502587 - 财政年份:2024
- 资助金额:
$ 6.16万 - 项目类别:
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
- 批准号:
2307223 - 财政年份:2024
- 资助金额:
$ 6.16万 - 项目类别:
Standard Grant
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 6.16万 - 项目类别:
Research Grant
Determining structural dynamics of membrane proteins in their native environment: focus on bacterial antibiotic resistance
确定膜蛋白在其天然环境中的结构动力学:关注细菌抗生素耐药性
- 批准号:
MR/X009580/1 - 财政年份:2024
- 资助金额:
$ 6.16万 - 项目类别:
Fellowship
CAREER: Systems Microbiology and InterdiscipLinary Education for Halting Environmental Antibiotic Resistance Transmission (SMILE HEART)
职业:阻止环境抗生素耐药性传播的系统微生物学和跨学科教育(SMILE HEART)
- 批准号:
2340818 - 财政年份:2024
- 资助金额:
$ 6.16万 - 项目类别:
Continuing Grant
Reinforcing the battle at the bacterial cell wall: Structure-guided characterization and inhibition of beta-lactam antibiotic resistance signalling mechanisms
加强细菌细胞壁的战斗:β-内酰胺抗生素耐药信号机制的结构引导表征和抑制
- 批准号:
480022 - 财政年份:2023
- 资助金额:
$ 6.16万 - 项目类别:
Operating Grants
The spread of antibiotic resistance in bacteria-plasmid networks
抗生素耐药性在细菌-质粒网络中的传播
- 批准号:
BB/X010473/1 - 财政年份:2023
- 资助金额:
$ 6.16万 - 项目类别:
Fellowship
An RNA Nanosensor for the Diagnosis of Antibiotic Resistance in M. Tuberculosis
用于诊断结核分枝杆菌抗生素耐药性的 RNA 纳米传感器
- 批准号:
10670613 - 财政年份:2023
- 资助金额:
$ 6.16万 - 项目类别: